Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434992 | 0.88 | ALDH1A1 (0.62) | NOTUMALDH1A1SRD5A1GAAMEN1 | |
| SCHEMBL14256038 | 0.86 | ALDH1A1 (0.56) | NOTUMALDH1A1SRD5A1GAAMEN1 | |
| SCHEMBL2625792 | 0.85 | ALDH1A1 (0.50) | NOTUMALDH1A1SRD5A1KMT2AHPGD | |
| SCHEMBL12905302 | 0.82 | NOTUM (0.53) | NOTUMALDH1A1SRD5A1GAAMEN1 | |
| SCHEMBL2333530 | 0.81 | MAPT (0.49) | NOTUMALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3154176 | 0.81 | MAPT (0.49) | NOTUMALDH1A1GAAMEN1KMT2A | |
| SCHEMBL18363028 | 0.80 | ALDH1A1 (0.44) | NOTUMALDH1A1SRD5A1GAAMEN1 | |
| SCHEMBL2625779 | 0.79 | NOTUM (0.57) | NOTUMALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2625777 | 0.79 | NOTUM (0.57) | NOTUMALDH1A1SRD5A1GAAMEN1 | |
| SCHEMBL10851045 | 0.79 | NOTUM (0.54) | NOTUMALDH1A1SRD5A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11706938-B2 | Photoelectric conversion element and photoelectric conversion module | RICOH COMPANY, LTD. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11706938-B2 | Photoelectric conversion element and photoelectric conversion module | RICOH COMPANY, LTD. (JP) | 2023-07-18 | — | — | US | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-20230171975-A1 | PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION MODULE, ELECTRONIC DEVICE, AND PARTITION | RICOH COMPANY, LTD., (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1803452-A1 | ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007071497-A1 | OXIME ESTER PHOTOINITIATORS | CIBA HOLDING INC. (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007062963-A1 | OXIME ESTER PHOTOINITIATORS | CIBA HOLDING INC. (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | HRH3, HRH4, HRH1 | NOTUM 1280/4885ALDH1A1 2111/4885SRD5A1 4435/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NOTUM 3827/4885ALDH1A1 355/4885SRD5A1 215/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | NOTUM 4556/4885ALDH1A1 4344/4885SRD5A1 2974/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | NOTUM 3826/4885ALDH1A1 3137/4885SRD5A1 2252/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | NOTUM 2504/4885ALDH1A1 1036/4885SRD5A1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.